(-)-epigallocatechin 3-gallate multiple interactions ISO RPS6KA5 (Homo sapiens) 6480464 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RPS6KA5 mRNA CTD PMID:22079256 1,2-dimethylhydrazine decreases expression ISO Rps6ka5 (Mus musculus) 6480464 1 and 2-Dimethylhydrazine results in decreased expression of RPS6KA5 mRNA CTD PMID:22206623 1-chloro-2,4-dinitrobenzene affects binding ISO RPS6KA5 (Homo sapiens) 6480464 Dinitrochlorobenzene binds to RPS6KA5 protein CTD PMID:32991956 17beta-estradiol multiple interactions ISO RPS6KA5 (Homo sapiens) 6480464 [Progesterone co-treated with Estradiol] results in decreased expression of RPS6KA5 mRNA CTD PMID:17404688 2,2',5,5'-tetrachlorobiphenyl decreases expression ISO RPS6KA5 (Homo sapiens) 6480464 2 more ... CTD PMID:36804509 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO Rps6ka5 (Mus musculus) 6480464 Tetrachlorodibenzodioxin results in decreased expression of RPS6KA5 mRNA CTD PMID:19933214 2,3,7,8-tetrachlorodibenzodioxine increases expression EXP 6480464 Tetrachlorodibenzodioxin results in increased expression of RPS6KA5 mRNA CTD PMID:34747641 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO Rps6ka5 (Mus musculus) 6480464 Tetrachlorodibenzodioxin promotes the reaction [RPS6KA5 protein binds to CYP1A1 enhancer] CTD PMID:24519526 3,3',5,5'-tetrabromobisphenol A decreases expression ISO Rps6ka5 (Mus musculus) 6480464 tetrabromobisphenol A results in decreased expression of RPS6KA5 mRNA CTD PMID:25172293 3,4-methylenedioxymethamphetamine decreases expression ISO Rps6ka5 (Mus musculus) 6480464 N-Methyl-3 and 4-methylenedioxyamphetamine results in decreased expression of RPS6KA5 mRNA CTD PMID:26251327 3,4-methylenedioxymethamphetamine decreases expression EXP 6480464 N-Methyl-3 and 4-methylenedioxyamphetamine results in decreased expression of RPS6KA5 mRNA CTD PMID:30071829 3,4-methylenedioxymethamphetamine decreases methylation ISO Rps6ka5 (Mus musculus) 6480464 N-Methyl-3 and 4-methylenedioxyamphetamine results in decreased methylation of RPS6KA5 promoter CTD PMID:26251327 4,4'-diaminodiphenylmethane increases expression ISO Rps6ka5 (Mus musculus) 6480464 4 and 4'-diaminodiphenylmethane results in increased expression of RPS6KA5 mRNA CTD PMID:18648102 4,4'-sulfonyldiphenol decreases methylation ISO Rps6ka5 (Mus musculus) 6480464 bisphenol S results in decreased methylation of RPS6KA5 promoter CTD PMID:33297965 4-hydroxyphenyl retinamide decreases expression ISO Rps6ka5 (Mus musculus) 6480464 Fenretinide results in decreased expression of RPS6KA5 mRNA CTD PMID:28973697 all-trans-retinoic acid decreases expression ISO RPS6KA5 (Homo sapiens) 6480464 Tretinoin results in decreased expression of RPS6KA5 mRNA CTD PMID:33167477 arsenite(3-) increases activity ISO Rps6ka5 (Mus musculus) 6480464 arsenite results in increased activity of RPS6KA5 protein CTD PMID:11689710 avermectin decreases phosphorylation ISO RPS6KA5 (Homo sapiens) 6480464 avermectin results in decreased phosphorylation of RPS6KA5 protein CTD PMID:33381906 benzene increases expression ISO RPS6KA5 (Homo sapiens) 6480464 Benzene results in increased expression of RPS6KA5 mRNA CTD PMID:33064461 benzo[a]pyrene decreases expression ISO Rps6ka5 (Mus musculus) 6480464 Benzo(a)pyrene results in decreased expression of RPS6KA5 mRNA CTD PMID:22228805 benzo[a]pyrene affects methylation ISO RPS6KA5 (Homo sapiens) 6480464 Benzo(a)pyrene affects the methylation of RPS6KA5 3' UTR CTD PMID:27901495 benzo[a]pyrene multiple interactions EXP 6480464 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Benzo(a)pyrene promotes the reaction [TNF protein results in increased expression of RPS6KA5 protein modified form]] and Benzo(a)pyrene promotes the reaction [TNF protein results in increased expression of RPS6KA5 protein modified form] CTD PMID:25233930 beta-naphthoflavone decreases expression ISO RPS6KA5 (Homo sapiens) 6480464 beta-Naphthoflavone results in decreased expression of RPS6KA5 mRNA CTD PMID:32858204 bis(2-chloroethyl) sulfide decreases expression ISO Rps6ka5 (Mus musculus) 6480464 Mustard Gas results in decreased expression of RPS6KA5 mRNA CTD PMID:18955075 bis(2-chloroethyl) sulfide increases phosphorylation ISO Rps6ka5 (Mus musculus) 6480464 Mustard Gas results in increased phosphorylation of RPS6KA5 protein CTD PMID:18200059 bis(2-ethylhexyl) phthalate decreases expression EXP 6480464 Diethylhexyl Phthalate results in decreased expression of RPS6KA5 mRNA CTD PMID:35810816 bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of RPS6KA5 mRNA CTD PMID:25181051 more ... bisphenol A increases expression ISO Rps6ka5 (Mus musculus) 6480464 bisphenol A results in increased expression of RPS6KA5 mRNA CTD PMID:35598803 bisphenol A increases methylation ISO RPS6KA5 (Homo sapiens) 6480464 bisphenol A results in increased methylation of RPS6KA5 gene CTD PMID:31601247 calcitriol decreases expression ISO RPS6KA5 (Homo sapiens) 6480464 Calcitriol results in decreased expression of RPS6KA5 mRNA CTD PMID:16002434 cannabidiol increases expression ISO RPS6KA5 (Homo sapiens) 6480464 Cannabidiol results in increased expression of RPS6KA5 mRNA CTD PMID:27918106 chloroprene increases expression EXP 6480464 Chloroprene results in increased expression of RPS6KA5 mRNA CTD PMID:23125180 cocaine increases expression EXP 6480464 Cocaine results in increased expression of RPS6KA5 mRNA and Cocaine results in increased expression of RPS6KA5 protein CTD PMID:17898221 and PMID:25100957 cocaine affects response to substance ISO Rps6ka5 (Mus musculus) 6480464 RPS6KA5 affects the susceptibility to Cocaine CTD PMID:16339038 cocaine increases activity ISO Rps6ka5 (Mus musculus) 6480464 Cocaine results in increased activity of RPS6KA5 protein CTD PMID:16339038 cocaine multiple interactions ISO Rps6ka5 (Mus musculus) 6480464 Cocaine results in increased phosphorylation of and results in increased activity of RPS6KA5 protein and SL 327 inhibits the reaction [Cocaine results in increased phosphorylation of and results in increased activity of RPS6KA5 protein] CTD PMID:16339038 copper atom multiple interactions ISO RPS6KA5 (Homo sapiens) 6480464 [Chelating Agents binds to Copper] which results in increased expression of RPS6KA5 mRNA CTD PMID:30911355 copper(0) multiple interactions ISO RPS6KA5 (Homo sapiens) 6480464 [Chelating Agents binds to Copper] which results in increased expression of RPS6KA5 mRNA CTD PMID:30911355 cyclosporin A increases expression ISO RPS6KA5 (Homo sapiens) 6480464 Cyclosporine results in increased expression of RPS6KA5 mRNA CTD PMID:20106945 decabromodiphenyl ether increases expression ISO RPS6KA5 (Homo sapiens) 6480464 decabromobiphenyl ether results in increased expression of RPS6KA5 protein CTD PMID:31675489 deoxynivalenol increases phosphorylation ISO Rps6ka5 (Mus musculus) 6480464 deoxynivalenol results in increased phosphorylation of RPS6KA5 protein CTD PMID:16424113 diclofenac decreases expression ISO Rps6ka5 (Mus musculus) 6480464 Diclofenac results in decreased expression of RPS6KA5 mRNA CTD PMID:26934552 dorsomorphin multiple interactions ISO RPS6KA5 (Homo sapiens) 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPS6KA5 mRNA CTD PMID:27188386 doxorubicin decreases expression ISO RPS6KA5 (Homo sapiens) 6480464 Doxorubicin results in decreased expression of RPS6KA5 mRNA CTD PMID:29803840 endosulfan increases expression EXP 6480464 Endosulfan results in increased expression of RPS6KA5 mRNA CTD PMID:29391264 ethyl methanesulfonate increases expression ISO RPS6KA5 (Homo sapiens) 6480464 Ethyl Methanesulfonate results in increased expression of RPS6KA5 mRNA CTD PMID:23649840 fasudil decreases activity ISO RPS6KA5 (Homo sapiens) 6480464 fasudil results in decreased activity of RPS6KA5 protein CTD PMID:10998351 fenvalerate decreases expression EXP 6480464 fenvalerate results in decreased expression of RPS6KA5 mRNA CTD PMID:30307764 folic acid decreases expression ISO Rps6ka5 (Mus musculus) 6480464 Folic Acid results in decreased expression of RPS6KA5 mRNA CTD PMID:25629700 formaldehyde increases expression ISO RPS6KA5 (Homo sapiens) 6480464 Formaldehyde results in increased expression of RPS6KA5 mRNA CTD PMID:23649840 FR900359 affects phosphorylation ISO RPS6KA5 (Homo sapiens) 6480464 FR900359 affects the phosphorylation of RPS6KA5 protein CTD PMID:37730182 gallic acid multiple interactions ISO RPS6KA5 (Homo sapiens) 6480464 Gallic Acid inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KA5 protein] CTD PMID:21420233 gentamycin increases expression EXP 6480464 Gentamicins results in increased expression of RPS6KA5 mRNA CTD PMID:33387578 hexane decreases methylation EXP 6480464 n-hexane results in decreased methylation of RPS6KA5 promoter CTD PMID:23740543 hydralazine multiple interactions ISO RPS6KA5 (Homo sapiens) 6480464 [Hydralazine co-treated with Valproic Acid] results in increased expression of RPS6KA5 mRNA CTD PMID:17183730 hydrogen peroxide increases activity ISO Rps6ka5 (Mus musculus) 6480464 Hydrogen Peroxide results in increased activity of RPS6KA5 protein CTD PMID:11689710 ivermectin decreases expression ISO RPS6KA5 (Homo sapiens) 6480464 Ivermectin results in decreased expression of RPS6KA5 protein CTD PMID:32959892 MeIQx increases expression ISO RPS6KA5 (Homo sapiens) 6480464 2-amino-3 more ... CTD PMID:20816883 metformin multiple interactions ISO RPS6KA5 (Homo sapiens) 6480464 [Metformin co-treated with Pioglitazone] results in decreased expression of RPS6KA5 mRNA CTD PMID:32589349 metformin decreases expression ISO RPS6KA5 (Homo sapiens) 6480464 Metformin results in decreased expression of RPS6KA5 mRNA CTD PMID:32589349 methoxychlor affects methylation EXP 6480464 Methoxychlor affects the methylation of RPS6KA5 gene CTD PMID:35440735 methyl methanesulfonate increases expression ISO RPS6KA5 (Homo sapiens) 6480464 Methyl Methanesulfonate results in increased expression of RPS6KA5 mRNA CTD PMID:23649840 mifepristone decreases expression EXP 6480464 Mifepristone results in decreased expression of RPS6KA5 mRNA CTD PMID:25972201 ML-7 decreases activity ISO RPS6KA5 (Homo sapiens) 6480464 ML 7 results in decreased activity of RPS6KA5 protein CTD PMID:12534346 N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide decreases activity ISO RPS6KA5 (Homo sapiens) 6480464 N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased activity of RPS6KA5 protein CTD PMID:10998351 and PMID:18377872 N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide decreases activity EXP 6480464 N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased activity of RPS6KA5 protein CTD PMID:15522277 nickel sulfate increases expression ISO RPS6KA5 (Homo sapiens) 6480464 nickel sulfate results in increased expression of RPS6KA5 mRNA CTD PMID:22714537 niclosamide increases expression ISO RPS6KA5 (Homo sapiens) 6480464 Niclosamide results in increased expression of RPS6KA5 mRNA CTD PMID:36318118 Nor-9-carboxy-delta9-THC multiple interactions ISO RPS6KA5 (Homo sapiens) 6480464 [Cannabinoids results in increased abundance of 11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid] which affects the methylation of RPS6KA5 gene CTD PMID:30521419 obeticholic acid decreases expression ISO RPS6KA5 (Homo sapiens) 6480464 obeticholic acid results in decreased expression of RPS6KA5 mRNA CTD PMID:27939613 oxaliplatin multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of RPS6KA5 mRNA CTD PMID:25729387 oxidopamine multiple interactions ISO Rps6ka5 (Mus musculus) 6480464 [benserazide more ... CTD PMID:17596448 and PMID:19187092 ozone multiple interactions ISO RPS6KA5 (Homo sapiens) 6480464 [Air Pollutants results in increased abundance of Ozone] which affects the expression of RPS6KA5 mRNA CTD PMID:35430440 paracetamol increases expression EXP 6480464 Acetaminophen results in increased expression of RPS6KA5 mRNA CTD PMID:33387578 paraquat increases expression ISO Rps6ka5 (Mus musculus) 6480464 Paraquat results in increased expression of RPS6KA5 mRNA CTD PMID:28012437 phenylephrine multiple interactions EXP 6480464 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of RPS6KA5 protein] more ... CTD PMID:15522277 and PMID:19002563 pioglitazone multiple interactions ISO RPS6KA5 (Homo sapiens) 6480464 [Metformin co-treated with Pioglitazone] results in decreased expression of RPS6KA5 mRNA CTD PMID:32589349 pirinixic acid multiple interactions ISO Rps6ka5 (Mus musculus) 6480464 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of RPS6KA5 mRNA CTD PMID:19710929 potassium chromate multiple interactions ISO RPS6KA5 (Homo sapiens) 6480464 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RPS6KA5 mRNA CTD PMID:22079256 potassium chromate decreases expression ISO RPS6KA5 (Homo sapiens) 6480464 potassium chromate(VI) results in decreased expression of RPS6KA5 mRNA CTD PMID:22079256 progesterone multiple interactions ISO RPS6KA5 (Homo sapiens) 6480464 [Progesterone co-treated with Estradiol] results in decreased expression of RPS6KA5 mRNA CTD PMID:17404688 quercetin increases phosphorylation ISO RPS6KA5 (Homo sapiens) 6480464 Quercetin results in increased phosphorylation of RPS6KA5 protein CTD PMID:18377872 quercetin multiple interactions ISO RPS6KA5 (Homo sapiens) 6480464 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Quercetin results in increased phosphorylation of RPS6KA5 protein] CTD PMID:18377872 Ro 31-8220 decreases activity EXP 6480464 Ro 31-8220 results in decreased activity of RPS6KA5 protein CTD PMID:15522277 SB 203580 multiple interactions ISO RPS6KA5 (Homo sapiens) 6480464 [U 0126 co-treated with SB 203580] inhibits the reaction [sodium arsenite results in increased activity of RPS6KA5 protein] and SB 203580 inhibits the reaction [sodium arsenite results in increased activity of RPS6KA5 protein] CTD PMID:12547826 SB 203580 multiple interactions EXP 6480464 SB 203580 inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of RPS6KA5 protein] CTD PMID:15522277 SB 431542 multiple interactions ISO RPS6KA5 (Homo sapiens) 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPS6KA5 mRNA CTD PMID:27188386 SCH 23390 multiple interactions ISO Rps6ka5 (Mus musculus) 6480464 SCH 23390 inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of RPS6KA5 protein] CTD PMID:19187092 silicon dioxide increases expression ISO RPS6KA5 (Homo sapiens) 6480464 Silicon Dioxide analog results in increased expression of RPS6KA5 mRNA CTD PMID:25895662 silicon dioxide decreases expression ISO Rps6ka5 (Mus musculus) 6480464 Silicon Dioxide results in decreased expression of RPS6KA5 mRNA CTD PMID:29203145 silver atom decreases expression ISO Rps6ka5 (Mus musculus) 6480464 Silver results in decreased expression of RPS6KA5 mRNA CTD PMID:27131904 silver(0) decreases expression ISO Rps6ka5 (Mus musculus) 6480464 Silver results in decreased expression of RPS6KA5 mRNA CTD PMID:27131904 SL-327 multiple interactions ISO Rps6ka5 (Mus musculus) 6480464 SL 327 inhibits the reaction [[benserazide more ... CTD PMID:16339038 and PMID:17596448 sodium arsenite multiple interactions ISO RPS6KA5 (Homo sapiens) 6480464 [U 0126 co-treated with SB 203580] inhibits the reaction [sodium arsenite results in increased activity of RPS6KA5 protein] more ... CTD PMID:12547826 sodium arsenite decreases expression EXP 6480464 sodium arsenite results in decreased expression of RPS6KA5 mRNA CTD PMID:35314868 sodium arsenite decreases expression ISO RPS6KA5 (Homo sapiens) 6480464 sodium arsenite results in decreased expression of RPS6KA5 mRNA CTD PMID:28595984 and PMID:34032870 sodium arsenite increases activity ISO RPS6KA5 (Homo sapiens) 6480464 sodium arsenite results in increased activity of RPS6KA5 protein CTD PMID:12547826 succimer multiple interactions ISO Rps6ka5 (Mus musculus) 6480464 [Succimer binds to Magnetite Nanoparticles] which results in decreased expression of RPS6KA5 mRNA CTD PMID:21641980 sunitinib increases expression ISO RPS6KA5 (Homo sapiens) 6480464 Sunitinib results in increased expression of RPS6KA5 mRNA CTD PMID:31533062 T-2 toxin decreases expression ISO RPS6KA5 (Homo sapiens) 6480464 T-2 Toxin results in decreased expression of RPS6KA5 mRNA CTD PMID:34581912 temozolomide increases expression ISO RPS6KA5 (Homo sapiens) 6480464 Temozolomide results in increased expression of RPS6KA5 mRNA CTD PMID:31758290 topotecan multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of RPS6KA5 mRNA CTD PMID:25729387 topotecan decreases expression EXP 6480464 Topotecan results in decreased expression of RPS6KA5 mRNA CTD PMID:25729387 trichostatin A increases expression ISO RPS6KA5 (Homo sapiens) 6480464 trichostatin A results in increased expression of RPS6KA5 mRNA CTD PMID:24935251 and PMID:26272509 trichostatin A multiple interactions ISO RPS6KA5 (Homo sapiens) 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPS6KA5 mRNA CTD PMID:27188386 urethane increases expression ISO RPS6KA5 (Homo sapiens) 6480464 Urethane results in increased expression of RPS6KA5 mRNA CTD PMID:28818685 valproic acid multiple interactions ISO RPS6KA5 (Homo sapiens) 6480464 [Hydralazine co-treated with Valproic Acid] results in increased expression of RPS6KA5 mRNA CTD PMID:17183730 valproic acid decreases methylation ISO RPS6KA5 (Homo sapiens) 6480464 Valproic Acid results in decreased methylation of RPS6KA5 gene CTD PMID:28853863 more ... valproic acid increases expression ISO RPS6KA5 (Homo sapiens) 6480464 Valproic Acid results in increased expression of RPS6KA5 mRNA CTD PMID:29154799 valproic acid decreases expression ISO RPS6KA5 (Homo sapiens) 6480464 Valproic Acid results in decreased expression of RPS6KA5 mRNA CTD PMID:23179753 and PMID:28001369 vinclozolin decreases expression EXP 6480464 vinclozolin results in decreased expression of RPS6KA5 mRNA CTD PMID:18042343 vinclozolin affects expression EXP 6480464 vinclozolin affects the expression of RPS6KA5 mRNA CTD PMID:19015723 Y-27632 decreases activity ISO RPS6KA5 (Homo sapiens) 6480464 Y 27632 results in decreased activity of RPS6KA5 protein CTD PMID:10998351
